ALUR vs. NSPR, SRTS, INO, MLSS, VANI, CTCX, EDAP, HYPR, APYX, and ZYXI
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include InspireMD (NSPR), Sensus Healthcare (SRTS), Inovio Pharmaceuticals (INO), Milestone Scientific (MLSS), Vivani Medical (VANI), Carmell (CTCX), Edap Tms (EDAP), Hyperfine (HYPR), Apyx Medical (APYX), and Zynex (ZYXI). These companies are all part of the "medical equipment" industry.
Allurion Technologies vs.
InspireMD (NYSE:NSPR) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Allurion Technologies received 3 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 66.67% of users gave Allurion Technologies an outperform vote while only 4.95% of users gave InspireMD an outperform vote.
InspireMD has higher earnings, but lower revenue than Allurion Technologies. InspireMD is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Allurion Technologies has a net margin of -71.24% compared to InspireMD's net margin of -413.96%. Allurion Technologies' return on equity of 0.00% beat InspireMD's return on equity.
44.8% of InspireMD shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 34.1% of InspireMD shares are held by company insiders. Comparatively, 22.4% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
InspireMD has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.
In the previous week, InspireMD had 3 more articles in the media than Allurion Technologies. MarketBeat recorded 3 mentions for InspireMD and 0 mentions for Allurion Technologies. InspireMD's average media sentiment score of 0.00 beat Allurion Technologies' score of -0.50 indicating that InspireMD is being referred to more favorably in the media.
InspireMD presently has a consensus price target of $4.50, suggesting a potential upside of 80.00%. Allurion Technologies has a consensus price target of $22.83, suggesting a potential upside of 737.92%. Given Allurion Technologies' higher probable upside, analysts clearly believe Allurion Technologies is more favorable than InspireMD.
Summary
Allurion Technologies beats InspireMD on 9 of the 17 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
This page (NYSE:ALUR) was last updated on 6/5/2025 by MarketBeat.com Staff
